Ann: Company Update, page-31

Could it be that the outgoing CEO (who doesn't live in Australia) didn't want to relocate with the rest of the operations? If the focus is now on revenue from illumen, revenue first then FDA later - could this realignment of resources come at a HR cost if the CEO wasn't prepared to relocate? I'd be assuming with operations in Australia where Jennifer is working hard to sign up and convert trials to paid agreements, this might allow for swifter movement, tighter control and greater take up??

All that said, when you look at the company announcement when they appointed Mr. Kaysen, - I'm wondering if this is a cost saving exercise esp. if they are delaying FDA submission (in terms of timing and resources).
https://medibio.com.au/medibio-appoints-global-healthcare-medical-device-leader-as-ceo-and-managing-director/